Compare BHP Billiton Limited (BHP) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BHP Billiton Limited vs Citius Pharmaceuticals Inc — how do they compare? BHP Billiton Limited trades at $90.66 (market cap $229.15B), while Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M). The key difference: BHP Billiton Limited is far larger — about 11451.8× Citius Pharmaceuticals Inc's market cap, and BHP Billiton Limited pays a 2.95% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BHP | CTXR | |
|---|---|---|
Market Cap | $229.15B | $20.01M |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $1.82 |
52-Week Low | $52.14 | $0.48 |
Enterprise Value | $243.35B | $16.23M |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BHP trades at $90.61, up 0.22% with a bullish technical signal supported by moving averages. The company reported mixed Q4 2025 earnings, missing EPS estimates but maintaining strong profitability with 18.97% net margins. Recent operational challenges include strikes at Port Hedland iron ore operations, while copper production declines in Chile. Valuation metrics show a P/E of 22.36 and P/B of 4.54, reflecting premium pricing relative to historical levels.
The outlook remains cautiously optimistic with analyst consensus leaning hold (64.52%) amid labor disputes and production volatility. Key opportunities include exposure to AI-driven copper demand growth, while risks center on strike impacts and fluctuating commodity prices. The stock's current technical strength faces fundamental headwinds from operational disruptions.
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
